You are here

Daiichi Sankyo

Seagen wins future royalties in Enhertu patent dispute

Pharmaphorum

Wed, 10/18/23 - 10:07 am

BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC

Fierce Biotech

Thu, 10/12/23 - 10:07 am

antibody-drug conjugate

Daiichi Sankyo reports positive results from trial of breast cancer therapy

Clinical Trials Arena

Mon, 09/25/23 - 11:47 am

clinical trials

AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead

BioSpace

Fri, 09/22/23 - 11:51 am

antibody-drug conjugate

clinical trials

AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind

Fierce Biotech

Tue, 09/12/23 - 12:00 pm

antibody-drug conjugate

non-small cell lung cancer

Daiichi Sankyo to close Japanese research and development subsidiary

Pharmaceutical Business Review

Tue, 08/8/23 - 10:17 am

Daiichi Sankyo will remain 'dominant' in ADC market for oncology treatments

Biopharma Reporter

Mon, 08/7/23 - 10:14 am

antibody drug conjugate

Enhertu offers survival benefits in Phase II solid tumour trial

Clinical Trials Arena

Sat, 07/29/23 - 10:42 pm

clinical trials

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

Pharmaphorum

Fri, 07/21/23 - 10:08 am

AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors

Fierce Biotech

Mon, 07/3/23 - 11:40 am

antibody-drug conjugate

clinical trials

non-small cell lung cancer

ASCO 2023 – early first-line lung cancer data mined for datopotamab gold

EP Vantage

Wed, 06/7/23 - 10:02 am

datopotamab deruxtecan

non-small cell lung cancer

ASCO puts spotlight on advancing antibody-drug conjugate pipeline

BioPharma Dive

Thu, 05/25/23 - 08:51 pm

antibody-drug conjugate

A blockbuster year could be building

EP Vantage

Wed, 05/10/23 - 09:55 am

Bristol Myers Squibb

Gilead Sciences

Horizon Therapeutics

Moderna Therapeutics

FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market

Fierce Biotech

Fri, 04/21/23 - 10:08 am

Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit

Fierce Pharma

Tue, 03/28/23 - 10:57 pm

Esperion Therapeutics

Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years

Fierce Biotech

Mon, 03/20/23 - 09:56 am

immuno-oncology

Daiichi torches Esperion’s Nexletol milestone promises

EP Vantage

Fri, 03/17/23 - 10:10 am

Esperion Therapeutics

Pages